These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 12480329

  • 1. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres.
    Diwan M, Tafaghodi M, Samuel J.
    J Control Release; 2002 Dec 13; 85(1-3):247-62. PubMed ID: 12480329
    [Abstract] [Full Text] [Related]

  • 2. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery.
    Diwan M, Elamanchili P, Cao M, Samuel J.
    Curr Drug Deliv; 2004 Oct 13; 1(4):405-12. PubMed ID: 16305402
    [Abstract] [Full Text] [Related]

  • 3. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.
    McCluskie MJ, Weeratna RD, Davis HL.
    Vaccine; 2001 Mar 21; 19(17-19):2657-60. PubMed ID: 11257405
    [Abstract] [Full Text] [Related]

  • 4. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
    Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM.
    J Immunol; 1998 Jan 15; 160(2):870-6. PubMed ID: 9551923
    [Abstract] [Full Text] [Related]

  • 5. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.
    Tafaghodi M, Sajadi Tabassi SA, Jaafari MR.
    Int J Pharm; 2006 Aug 17; 319(1-2):37-43. PubMed ID: 16701972
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.
    Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV.
    J Exp Med; 1997 Nov 17; 186(10):1623-31. PubMed ID: 9362523
    [Abstract] [Full Text] [Related]

  • 11. CpG ODN 2006 and IL-12 are comparable for priming Th1 lymphocyte and IgG responses in cattle immunized with a rickettsial outer membrane protein in alum.
    Zhang Y, Palmer GH, Abbott JR, Howard CJ, Hope JC, Brown WC.
    Vaccine; 2003 Jul 04; 21(23):3307-18. PubMed ID: 12804862
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immunoadjuvant potential of cross-linked dextran microspheres mixed with chitosan nanospheres encapsulated with tetanus toxoid.
    Pirouzmand H, Khameneh B, Tafaghodi M.
    Pharm Biol; 2017 Dec 04; 55(1):212-217. PubMed ID: 27927058
    [Abstract] [Full Text] [Related]

  • 16. A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine.
    Sugai T, Mori M, Nakazawa M, Ichino M, Naruto T, Kobayashi N, Kobayashi Y, Minami M, Yokota S.
    Vaccine; 2005 Nov 16; 23(46-47):5450-6. PubMed ID: 16006019
    [Abstract] [Full Text] [Related]

  • 17. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.
    Weeratna RD, Brazolot Millan CL, McCluskie MJ, Davis HL.
    FEMS Immunol Med Microbiol; 2001 Dec 16; 32(1):65-71. PubMed ID: 11750224
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.